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The Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib is inducing durable responses in chronic lymphocytic leukemia (CLL)
patients with refractory/relapsed disease or with TP53 defect, with BTK and phospholipase C gamma 2 (PLCG2) mutations
representing the predominant mechanisms conferring secondary ibrutinib resistance. To understand the landscape of genomic
changes and the dynamics of subclonal architecture associated with ibrutinib treatment, an ultra-deep next-generation
sequencing analysis of 30 recurrently mutated genes was performed on sequential samples of 20 patients, collected before
and during single-agent ibrutinib treatment. Mutations in the SF3B1, MGA and BIRC3 genes were enriched during ibrutinib
treatment, while aberrations in the BTK, PLCG2, RIPK1, NFKBIE and XPO1 genes were exclusively detected in posttreatment
samples. Besides the canonical mutations, four novel BTK mutations and three previously unreported PLCG2 variants were
identiﬁed. BTK and PLCG2 mutations were backtracked in ﬁve patients using digital droplet PCR and were detectable on
average 10.5 months before clinical relapse. With a median follow-up time of 36.5 months, 7/9 patients harboring BTK
mutations showed disease progression based on clinical and/or laboratory features. In conclusion, subclonal heterogeneity,
dynamic clonal selection and various patterns of clonal variegation were identiﬁed with novel resistance-associated BTK
mutations in individual patients treated with ibrutinib.
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Introduction
Chronic lymphocytic leukemia (CLL) is characterized by sub-
stantial clinical and genetic heterogeneity. Recent whole-exome
and whole-genome sequencing studies unraveled recurrently
mutated driver genes in CLL, including ATM, NOTCH1,
SF3B1, BIRC3, NKFBIE, MYD88 and TP53, and identiﬁed
clonal evolution as the major mechanism driving disease pro-
gression in the context of standard chemo-immunotherapy.1–7
Patients with TP53 aberrations have typically been character-
ized by refractoriness to standard therapies and particularly
poor outcome with rapid selection of the resistant clones dur-
ing standard therapies.8,9
The irreversible Bruton’s tyrosine kinase (BTK) inhibitor,
ibrutinib has been changing the treatment paradigm of CLL
with remarkable outcomes in ﬁrst line as well as in relapsed
CLL, including high-risk patients with 17p deletion and/or
TP53 mutation.10–13 Despite the durable responses observed
in the majority of patients, approximately 20% of them
develop resistance, with mutations in the BTK and phospholi-
pase C gamma 2 (PLCG2) genes representing the predominant
mechanisms conferring secondary ibrutinib resistance.14,15
The loss of function BTK Cys481 mutations leading to
impaired ibrutinib binding and/or the gain of function PLCG2
Arg665Trp/Ser707Tyr/Leu845Phe mutations resulting in con-
tinuous B-cell receptor (BCR) signaling can be detected in the
vast majority of ibrutinib resistant patients.16–18 Based on ini-
tial studies, these mutations are commonly present in multiple
independent subclones suggesting parallel clonal evolution
and their emergence predates clinical progression and
relapse.16,18 Indeed, clonal shifts identiﬁed by whole-exome
sequencing during the early periods of ibrutinib treatment in
one-third of the patients were associated with disease progres-
sion, reﬂecting great evolutionary capacity potentially leading
to emergence of drug-resistant clones.19 Given the abysmal
outcome of patients discontinuing ibrutinib, comprehensive
characterization of mechanisms underlying ibrutinib resis-
tance and the related changes in the subclonal architecture
induced by the selective pressure of the treatment have major
clinical importance and represent an urgent unmet need.20
To dissect the clonal evolution affecting all relevant mutation
targets in CLL in the context of ibrutinib therapy, we performed
a temporal mutation proﬁling by analyzing 30 genes in paired
pretreatment and posttreatment samples of CLL patients receiv-
ing ibrutinib therapy outside the setting of a clinical trial.
Materials and Methods
Patient samples
Sequential samples from 20 consecutive patients (12 males and
8 females), with a median age of 63 years treated with single-
agent ibrutinib were included in our study with clinical charac-
teristics listed in Supporting Information Table S1. Our cohort
represented a pretreated patient group with a median of 2 (range:
1–5) lines of prior therapies. These patients were initially
granted access to ibrutinib via a case by case individual applica-
tion process available in Hungary since July 2014, with ibrutinib
fully supported by the National Health Insurance Fund from
2017. Pretreatment peripheral blood mononuclear cells (PBMC)
were available from all patients, with matching posttreatment
samples as outlined in Figure 1a. The IGHV mutation status
was determined according to the most recent European
Research Initiative on CLL recommendations21 with deletions
13q, 11q and 17p, as well as trisomy 12 analyzed by interphase
ﬂuorescence in situ hybridization using Vysis probe sets (Abbott
Molecular, Lake Bluff, IL). The proportion of CLL cells in the
samples was assessed by ﬂow cytometry using CD5/CD19/
CD23/CD45 staining. PBMC-derived DNA samples from ﬁve
healthy volunteers were used as negative controls. Written
informed consent from all patients was obtained for the study
which was conducted in accordance with the Declaration of
Helsinki and approved by the Hungarian Medical Research
Council.
Customized ultradeep next-generation sequencing
Targeted ultra-deep next-generation sequencing (NGS) analysis
of 30 recurrently mutated genes, including ATM, BCOR, BIRC3,
BRAF, BTK, CHD2, DDX3X, EGR2, EIF2A, EP300, FBXW7, HIS-
T1H1E, IGLL5, KLHL6, KMT2D, LRP1B, MED12, MGA,
MYD88, NFKBIE, NOTCH1, PLCG2, POT1, RIPK1, RPS15,
SAMHD1, SF3B1, TP53, XPO1 and ZMYM3 (Supporting Infor-
mation Table S2) with a published frequency of ≥2%1,2,4–7 was
performed using the TruSeq Custom Amplicon approach
(Illumina, San Diego, CA) with maximum input of genomic
DNA samples extracted from PBMCs. After quality control and
equimolar pooling, libraries were sequenced on a HiSeq 4000
Instrument (Illumina) using 150 bp paired-end chemistry. The
variant allele frequencies (VAF) were normalized considering
the proportion of CLL cells as determined by ﬂow cytometry.
The median follow-up time at the time of the NGS analysis was
22.5 months (range: 3–34 months).
What’s new?
Although the Bruton’s tyrosine kinase (BTK) inhibitor, ibrutinib has revolutionized the treatment of chronic lymphocytic
leukemia, 20% of patients still show disease progression. Comprehensive characterisation of mechanisms underlying ibrutinib
resistance and the related changes in the subclonal architecture induced by the selective pressure of the treatment may usher
in new clinical advances. This time-resolved ultra-deep genomic scrutiny of mutation target genes reveals unique patterns of
highly dynamic clonal variegation associated with BTK inhibition and identiﬁes novel resistance-associated BTK mutations in
individual patients. Furthermore, evidence suggests that sensitive molecular monitoring of treatment response can facilitate
the early detection of impending relapse.
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Figure 1. (a) Timeline and basic cytogenetic features of the 20 patients treated with ibrutinib. Red circles denote patients who progressed on
ibrutinib with a BTK or PLCG2 mutation as determined by next-generation sequencing. (b) Heat map displaying the somatic variants detected
in the 30 target genes analyzed in the sequential samples of 20 patients treated with ibrutinib. Illustrated are the distribution of the somatic
variants, mutation status of the IGHV gene segment, cytogenetic proﬁle as determined by ﬂuorescence in situ hybridization, as well as the
mutation frequency of the individual genes for all cases. (c) Comparison of the mutation frequency in the 30 genes analyzed between the
pretreatment and posttreatment specimens. (d) Different patterns of clonal composition and dynamics in four selected patients with TP53
mutations. Convergent mutation evolution was frequently observed with acquisition of multiple mutations within a gene, exempliﬁed by
multiple TP53 mutations in Patients #2 and #20. Interestingly, TP53 mutations showed a similar tendency to undergo clonal expansion or
elimination under ibrutinib therapy.
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Bioinformatics workﬂow
During data preprocessing, sequencing reads were mapped to the
Homo sapiens GRCh37 genome build using BWA v0.7.13 aligner
from the BaseSpace Sequence Hub. BAM ﬁles were sorted and
indexed by SAMtools v1.7 module and GATK v4.0 tool. Base
Quality Score Recalibration was run on each sample to detect and
correct systematic sequencing errors. Single nucleotide variant
(SNV) and INDEL calling were performed with LoFreq v2.1
variant-caller22 that considers all dataset features, also including
base-call qualities, mapping problems or base/INDEL misalign-
ments, which are commonly ignored by other methods or only
used for ﬁltering. Assignment of each detected variant with a p-
value allowed for a rigorous control of false positive ﬁndings. Raw
variants, detected by LoFreq v2.1, were functionally annotated
using SnpEff v4.3i as well as ANNOVAR v2017Jul17 tools, with
the latter one also including up-to-date information from COS-
MIC, avSNP and CLINVAR databases.23,24 In addition, variants
in the TP53 coding region were annotated using the
TP53-speciﬁc Seshat and IARC databases.25,26 The raw sequenc-
ing data was uploaded to the European Nucleotide Archive
(https://www.ebi.ac.uk/ena, Primary Accession: PRJEB32120, Sec-
ondary Accession: ERP114759).
Validation of somatic variants
Bidirectional Sanger sequencing was applied to validate all
somatic variants with a VAF of >20% (Supporting Information
Table S3) using primers listed in Supporting Information
Table S4 with the detailed results presented in Supporting Infor-
mation Figure S1. BTK Cys481Ser and PLCG2 Asp993His
mutations were validated by droplet digital PCR (ddPCR;
Supporting Information Fig. S2). Reactions were performed with
50 ng input DNA using locus-speciﬁc assays for the wild type
and mutant targets (Supporting Information Table S5) following
the manufacturer’s protocol. Droplets were created by the QX200
Automated Droplet Generator and reading was completed with
the QX200 ddPCR system (Bio-Rad, Hercules, CA). Results were
analyzed using the Bio-Rad QuantaSoft software. The BTKmut or
PLCG2mut allelic burden was determined as fractional abundance
(FA) based on the percentage ratio between the number of
mutant DNA molecules (a) and the number of mutant (a) plus
wild-type (b) molecules detected [FA = a/(a + b)].
Results
Mutational landscape of the ibrutinib treated cohort
The ultra-deep NGS revealed a total of 211 somatic variants in
the 20 paired samples with an average allelic depth of 7,500×
across the 30 genes analyzed (Fig. 1b, Supporting Information
Table S6). The majority (157/211) of the variants represented
subclonal alterations with VAF of <10% (Supporting Informa-
tion Fig. S3). A remarkable subclonal heterogeneity was detected
across the cases with an average of ﬁve mutations (range: 0–19)
detected in individual patients, affecting an average of four genes
(range: 0–18; Supporting Information Fig. S4). NOTCH1 (70%,
14/20), ATM (70%, 14/20), TP53 (65%, 13/20) and BCOR (55%,
11/20) represented the most frequently mutated target genes
(Fig. 1b). All somatic variants with a VAF of >20% were success-
fully validated by Sanger sequencing.
Figure 1. Continued
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Temporal dissection of the mutational landscape
The posttreatment samples carried a slightly higher number
of variants compared to the pretreatment samples (118 vs.
93), with an average of 5.9 mutations (range: 1–16) in the
posttreatment specimens and on average 4.7 mutations in the
pretreatment samples (range: 0–19; Supporting Information
Fig. S4). Temporally, NOTCH1, ATM, TP53 and BCOR repre-
sented the top four mutated target genes at baseline as well as
posttreatment (Fig. 1c). While IGLL5, EIF2A and EP300 muta-
tions were eliminated from the posttreatment samples, we
observed an enrichment of SF3B1 (5% vs. 40%), MGA (5% vs.
30%), BIRC3 (10% vs. 30%) mutations in the posttreatment
samples compared to the pretreatment specimens (Fig. 1c),
with a three-fold increase in mutation frequencies of MYD88
and LRP1B genes after ibrutinib treatment (Fig. 1c). BTK,
PLCG2, RIPK1, NFKBIE and XPO1 mutations were exclusively
detected in the posttreatment samples in 35, 15, 10, 5 and 5%
of the patients, respectively (Fig. 1c).
Various combinations of mutations were identiﬁed in all
patients (Supporting Information Fig. S5). Convergent mutation
evolution (CME) deﬁned as acquisition of multiple mutations in
the same gene27 was identiﬁed in 40% (12/30) of the genes ana-
lyzed, with 2–4 mutations detected within a particular target
gene (Fig. 1b). Overall, CME was observed in 50% (10/20) of
patients, with this phenomenon documented in both pre-
treatment and posttreatment samples in four patients and in
either pretreatment or posttreatment samples of three patients.
Subclonal dynamics of TP53, BTK and PLCG2 mutations
Mutations in the BTK or PLCG2 genes previously found to be
associated with ibrutinib resistance were detected in 40% (8/20)
and 5% (1/20) of the patients, respectively, with mutations exclu-
sively detected in the posttreatment samples (Figs. 1b and 1c).
The BTK and PLCG2 variants co-occurred in 2/8 patients carry-
ing mutations in one of these genes with 1–4 variants present in
individual patients (Supporting Information Table S6). In addi-
tion to the canonical BTK Cys481 and PLCG2 Asp993 hotspots,
four novel BTK mutations at residues Arg28, Gly164, Arg490 and
Gln516 were identiﬁed (Fig. 2a), with three previously unreported
PLCG2 mutations at Phe82, Arg694 and Ser1192 (Fig. 2b), affect-
ing altogether four different patients. Changes in the mutational
composition and heterogeneity between the pretreatment and
posttreatment samples of patients progressing on ibrutinib with
BTK/PLCG2mutations are illustrated in Supporting Information.
Of special interest were the frequent multiple TP53 mutations
characterized by either elimination or expansion of the mutant
clone, or elimination of the TP53 mutant subclone and concur-
rent emergence of an independent subclone with TP53
mutation(s) in the posttreatment sample, as illustrated by
Patients #20, #17, #8 and #2, respectively (Fig. 1d). Notably, an
alternating dynamics of BTK and TP53 mutations was observed
in almost all patients carrying both alterations in any of their
samples. The emergence of BTK mutations upon ibrutinib treat-
ment was accompanied by the concurrent decrease of TP53
mutational abundance. Among the six patients harboring BTK
Cys481 mutations (Patients #1, #5, #6, #10, #11 and #20), all four
patients carrying TP53 mutations (Patients #1, #5, #11 and #20)
demonstrated clonal elimination or reduction of the TP53 alter-
ation in the posttreatment sample. Elimination of a TP53 muta-
tion was also observed in Patient #17, acquiring a noncanonical
BTKmutation upon ibrutinib treatment. On the other hand, sub-
clones carrying TP53 mutations persisted or expanded in 8/20
patients (Patients #2, #3, #7, #8, #12, #13, #15 and #18), among
whom only Patient #3 carried two previously unknown BTK
mutations with currently ambiguous clinical signiﬁcance. Indeed,
canonical BTK Cys481 mutations were never observed in patients
with detectable TP53mutation in the posttreatment sample.
Clinical outcome and follow-up of patients
Clinically, with an extended median follow up time of
36.5 months (range: 3–43 months) documented after performing
the initial NGS analysis, 65% (13/20) of patients remain on
ibrutinib with at least partial or complete remission. Three
patients (Patients #9, #10 and #17) underwent Richter’s transfor-
mation and succumbed to their disease at months 4, 30 and
18, respectively (Fig. 1a, Supporting Information Fig. S6). While
in Patient #10, the disease progression was associated with the
known BTK Cys481Ser and PLCG2 Asp993His mutations28, in
Patient #9 and Patient #17, the previously unreported BTK
Gln516Lys and Arg490His mutations appeared to be linked with
disease progression (Fig. 1a, Supporting Information Fig. S6). In
Patient #1, two BTK Cys481 mutations emerged at month
34, when the patient received venetoclax treatment, showed a
good response and is currently in remission at month 40. Patient
#2 died of a secondary tumor (colon cancer) with an expanding
TP53 mutant clone 27 months after starting ibrutinib therapy.
Patient #6 with a BTK Cys481Ser mutation died of septicemia at
month 30 with a stable disease (Fig. 1a, Supporting Information
Fig. S6). A BTK Cys481Ser mutation was detected in Patient
#11 at month 24, with documented laboratory progression char-
acterized by a gradual increase of lymphocyte count. Patient #3
developed two previously unreported BTK (Arg28Ser and
Gly164Asp) and two novel PLCG2 (Phe82Ser and Ser1192Gly)
mutations by month 18 and is still in clinical remission at month
40 on ibrutinib therapy. Patient #19 acquired a PLCG2
Arg694His variant (previously unreported in CLL) at month
8 on ibrutinib treatment and died without CLL progression due
to a secondary tumor (malignant melanoma) within 2 months.
Monitoring of BTK Cys481Ser and PLCG2 Asp993His
mutations using digital droplet PCR
Twelve and 15 months after the time of the latest sample collec-
tion for NGS analysis, Patients #5 and #20 also acquired BTK
Cys481Ser mutation at months 44 (VAF: 0.03%) and 32 (VAF:
10.1%) post-ibrutinib, respectively, as identiﬁed by ddPCR.
These patients are demonstrating laboratory progression at the
moment, with permanently increasing lymphocyte count with-
out clinically manifest progression to date.
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Using serial samples and a highly sensitive (0.01%) digital
droplet PCR (ddPCR) assay, we retrospectively backtracked the
BTK/PLCG2 mutations in Patients #5 and #20 and in three addi-
tional patients (Patients #1, #10 and #11) to determine the earli-
est time point in the clonal history when the mutations gained
selective advantage. The BTK/PLCG2 variants emerged on aver-
age 10.5 months (range: 7–15 months) before the clinical relapse
with low fractional abundance (Fig. 3). In Patient #11, laboratory
progression developed 10 months after the ﬁrst detection of the
BTK Cys481Ser mutation. In Patients #1 and #10, we also dem-
onstrated the reduction of the BTK mutant subclones upon ven-
etoclax treatment (Fig. 3). The extended clonal history of Patient
#10 including spatial mutation proﬁling was previously
published.27
Overall, 78% (7/9) of the patients with BTKmutations showed
laboratory or clinical disease progression with these mutations
predating relapse by several months (Supporting Information
Fig. S6), while no progression occurred without underlying BTK
mutations in our cohort. In all three patients with Richter
syndrome, the BTK mutations emerged within the ﬁrst 2 years
(4–18 months) of ibrutinib therapy, while patients with CLL pro-
gression acquired BTK mutations after a longer exposure to
ibrutinib (21–28 months), suggesting that early acquisition of
BTKmutations may predict a rapidly progressing disease course.
Discussion
Ibrutinib has remarkably changed the landscape of CLL ther-
apy by inducing durable responses in patients with previously
Figure 2. (a) Schematic domain structure of BTK with variants observed in our study cohort and/or identiﬁed by previous studies. We observed
mutations within the PH, TH and TK domains of the protein. (PH: Pleckstrin homology; TH: Tec homology; SH3/2: Src homology 3/2; TK: Tyrosine kinase).
Variants highlighted with red were detected in patients with CLL, while purple variants were observed in patients with Richter’s transformation. BTK
R28S, G164D, R490H and Q516K represent previously unreported variants, based on the COSMIC database. (b) Schematic domain structure PLCG2 with
variants observed in our study cohort and/or identiﬁed by previous studies. (EF: EF-hand motifs; X: X domain; SH2/3: Src homology 2/3; Y: Y domain;
C2: calcium-binding motif) Variants highlighted with red were detected in patients with CLL, while purple variants were observed in patients with
Richter’s transformation. PLCG2 F82S and S1192G are previously unreported variants not annotated in COSMIC database. The PLCG2 R694H variant was
previously reported in two colon cancer cases (COSM2693625); however, it represents a novel ﬁnding in CLL.
6 Clonal evolution in CLL patients treated with ibrutinib
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relapsed/refractory disease as well as in high-risk patients har-
boring TP53 aberrations.13 However, the extent and landscape
of subclonal changes occurring under the selective pressure of
ibrutinib have not completely been dissected yet. Here, we
performed an ultra-deep NGS analysis of 30 mutation target
genes on a “real-world” patient cohort treated with ibrutinib.
Dynamic clonal selection emerging on the ground of a pro-
found subclonal heterogeneity and commonly conferring con-
vergent evolution was observed in the vast majority of
patients. Scrutiny of the clonal trajectories revealed that all
individual cases were characterized by unique combinations of
mutations as well as different patterns of clonal variegation
upon the selective pressure exerted by ibrutinib. In contrast to
clonal selection conferred by chemo-immunotherapy, no
mutations in the main driver genes involved in pathogenesis
of CLL demonstrated selective ﬁtness to ibrutinib. Our study
cohort represented a pretreated patient group with up to ﬁve
lines of standard chemo-immunotherapies, hence the sub-
clonal architecture prior to ibrutinib therapy was reshaped
multiple times consecutively. The common presence of sub-
clonal mutations detected in virtually all genes analyzed in
our study is in line with a recent observation by Nadeu et al.
reporting for the ﬁrst time that mutations emerging sub-
clonally are more common in CLL as compared to clonal
mutations, and the extent of subclonal heterogeneity has an
inﬂuence on the survival of CLL patients.28 This was con-
ﬁrmed and extended by Leeksma et al. documenting increased
subclonal heterogeneity and signiﬁcant enrichment of recur-
rent gene mutations in chemotherapy refractory patients as
compared to treatment naïve cases, in a cohort of
643 patients.29
Although in clinical terms, response to ibrutinib appears
to be independent of TP53 aberrations, patients with TP53
defects relapse more frequently, suggesting a complex biology
behind TP53 deregulation. Indeed, the TP53 mutant sub-
clones observed in our study showed variable scenarios with
undergoing clonal expansion or reduction, or elimination of
a TP53 mutant subclone coupled with concurrent acquisition
of another subclone with different TP53 mutation, indicating
great evolutionary capacity and a differential sensitivity of
the various TP53 mutations to ibrutinib. Intriguingly, analy-
sis of the subclonal architecture identiﬁed a novel alternating
pattern of clonal dynamics of BTK and TP53 mutations. The
majority of BTK mutations were detectable after reduction or
elimination of TP53 mutated subclones and conversely, were
never acquired on the ground of persisting or expanding
TP53 mutated subclones. Although this ﬁnding should be
conﬁrmed in larger patient cohorts, one may speculate that
elimination of the TP53 mutant subclones may be a prereq-
uisite for the expansion of subclones harboring BTK muta-
tions in those cases where both mutations are present in any
time during disease course. Another alternative would be
that the prolonged duration of ibrutinib treatment (in our
cohort, 2.5–3 years) simply creates niche for subclones
Figure 3. Digital droplet PCR assay was employed to track the BTK Cys481Ser and PLCG2 Asp993His mutations in ﬁve patients. The BTK/
PLCG2 variants were detected on average 10.5 months before clinical relapse. For Patients #1 and #10, illustrated are the clonal changes of
BTK and PLCG2 mutations after venetoclax treatment.
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harboring various BTK mutations by gradually eliminating
the TP53 subclones.
With a median follow up time of 36.5 months, 35% (7/20)
of the patients relapsed with a BTK or PLCG2 mutation in
our cohort. With our study, we reinforced and extended the
central role of BTK and PLCG2 mutations in ibrutinib resis-
tance by identifying novel putative mutation sites in the BTK
gene with two previously unreported BTK mutations
(Arg490His and Gln516Lys) in two of the patients displaying
ibrutinib resistance and rapid disease progression. We also
provide evidence that early and sensitive detection of BTK
mutations may be predictive of an impending relapse. After
the initial discovery of the canonical BTK and PLCG2 muta-
tions underlying ibrutinib resistance by whole exome sequenc-
ing studies,14,15 additional mutations were described in
various domains of these two genes, predominantly detected
in single patients with low VAFs.16,17,30–32 As in many of the
initial studies, only mutation hotspots were analyzed or NGS
studies were performed with a relatively low sequencing
depth, the clonal complexity of ibrutinib resistance in the con-
text of BTK and PLCG2 mutations may well have been under-
estimated. Our study and some of the most recent data in the
literature suggest that comprehensive deep-sequencing of
these driver genes instead of a restrictive analysis of mutation
hotspots may be of added clinical value in the future. In addi-
tion, genomic proﬁling of multiple sites, such as peripheral
blood, bone marrow and lymph nodes providing distinct
microenvironments for parallel clonal evolution should be
considered in order to achieve a precise characterization of
CLL in individual patients.27
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